These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 4557763)
21. [Madecassol in the treatment of scleroderma (preliminary study)]. Szczepański A; Dabrowska H; Blaszczyk M Przegl Dermatol; 1974; 61(5):701-3. PubMed ID: 4419170 [No Abstract] [Full Text] [Related]
22. Avocado/soybean unsaponifiables in the treatment of scleroderma: comment on the article by Maheu et al. Jablonska S Arthritis Rheum; 1998 Sep; 41(9):1705. PubMed ID: 9751109 [No Abstract] [Full Text] [Related]
26. [Treatment of systemic scleroderma with high dosage of intravenous hyaluronidase]. Petter O; Bellmann H Hautarzt; 1971 Jan; 22(1):32-3. PubMed ID: 4251354 [No Abstract] [Full Text] [Related]
27. [Piascledine in the treatment of scleroderma]. Szczepański A; Dabrowska H; Moskalewska K Przegl Dermatol; 1974; 61(4):525-7. PubMed ID: 4849404 [No Abstract] [Full Text] [Related]
28. [Theoretical aspects of the new possibilities of use of hyaluronidase]. Petter O; Bellmann H Z Gesamte Inn Med; 1971 Mar; 26(5):171-4. PubMed ID: 5560774 [No Abstract] [Full Text] [Related]
30. Salazopyrin (azulfidine) treatment in scleroderma. Dover N Isr J Med Sci; 1971 Nov; 7(11):1301-3. PubMed ID: 4400695 [No Abstract] [Full Text] [Related]
31. [Treatment of some sclerosing processes with uropancreozymin]. Hodác V; Svatos A Cesk Dermatol; 1971 Apr; 46(2):83-6. PubMed ID: 5564727 [No Abstract] [Full Text] [Related]
32. Stimulating circulation to end stasis in scleroderma. Yuan X; Li JD; Chen WJ; Li ZS; Zhu HT; Liu JW; Zhu MJ Chin Med J (Engl); 1981 Feb; 94(2):85-93. PubMed ID: 6786844 [No Abstract] [Full Text] [Related]
33. [Effect of piascledine treatment of scleroderma]. Szczepański A; Dabrowska H; Moskalewska K Przegl Dermatol; 1975; 62(4):555-8. PubMed ID: 1162105 [No Abstract] [Full Text] [Related]
34. Clinical trials for the treatment of systemic sclerosis/scleroderma. Varga J; Ponor I Curr Rheumatol Rep; 1999 Oct; 1(1):13-4. PubMed ID: 11123008 [No Abstract] [Full Text] [Related]
35. [Scleroderma and dermatomyositis]. Meinhof W Med Welt; 1972 Nov; 23(45):1650-3. PubMed ID: 4637705 [No Abstract] [Full Text] [Related]
36. Hyaluronidase as a Successful Treatment Modality for Scleroderma-Induced Microstomia. Chopra D; Brehm JE; Morrison B Dermatol Surg; 2022 Sep; 48(9):1014-1015. PubMed ID: 35834642 [No Abstract] [Full Text] [Related]
37. [The prognosis and treatment of scleroderma]. Degos R Rev Prat; 1975 May; 25(25):2003-4, 2005-7. PubMed ID: 1135588 [No Abstract] [Full Text] [Related]
38. [Investigations on the mode of action of D-penicillamine (Metalcaptase) in sclerodermia]. Daróczy J; Gyöngyvér S Munch Med Wochenschr; 1973 Aug; 115(31):1363-7. PubMed ID: 4741080 [No Abstract] [Full Text] [Related]
39. [Low-molecular dextran (40,000) in the treatment of scleroderma]. Szczepański A; Zielińska Z; Polkowska M; Lorenc B Przegl Dermatol; 1975; 62(1):79-82. PubMed ID: 1111035 [No Abstract] [Full Text] [Related]
40. Use of hyaluronidase in scleroderma. CLAESSON U; LINDQUIST B Acta Paediatr (Stockh); 1953 May; 42(3):278-81. PubMed ID: 13079763 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]